Product Information

QUETIAPINE FUMARATE 300 MG TAB is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.1278 per EA under NDC 16571072101. Its NADAC has been published 246 times since Mar 2, 2022.

FDA first approved this application on Mar 27, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

QUETIAPINE FUMARATE 300 MG TAB

Quetiapine Fumarate
$0.1278per EA

Strength

300 mg/1

NDC

16571072101

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

QUETIAPINE FUMARATE

Approval Type

Generic (ANDA)

FDA Application

ANDA091388

FDA Approved

3/27/2012

TE Code

AB

On Market Since

3/27/2012

Pharmacological Classes

Price Statistics

The NADAC for QUETIAPINE FUMARATE 300 MG TAB has been published 246 times since Mar 2, 2022, and over the history we have for it it has declined 27.1%. The table below summarizes its recorded NADAC range and movement.

Current price$0.1278 per EA
All-time high$0.1904 (Mar 13, 2024)
All-time low$0.1136 (Nov 20, 2024)
52-week high$0.1465
52-week low$0.1265
Median price$0.1408
Average price$0.1430
Largest weekly change-26.7% (Nov 20, 2024)
Weeks tracked246
Tracking sinceMar 2, 2022

Price History

1W

0.0%

1M

+0.2%

3M

-0.6%

6M

-12.8%

1Y

-6.2%

3Y

-13.4%

5Y

N/A

All

-27.1%

Generic Alternatives

The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 0% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of QUETIAPINE FUMARATE 300 MG TAB?

The current National Average Drug Acquisition Cost (NADAC) for QUETIAPINE FUMARATE 300 MG TAB, manufactured by Rising Pharma Holdings Inc., is $0.1278 per EA (NDC 16571072101), effective Nov 11, 2026.

How has the price of QUETIAPINE FUMARATE 300 MG TAB changed over time?

Over the history we have for it, the NADAC for QUETIAPINE FUMARATE 300 MG TAB has declined 27.1%. It has been tracked across 246 weekly CMS publications since Mar 2, 2022.

What are the highest and lowest recorded NADAC prices for QUETIAPINE FUMARATE 300 MG TAB?

Since Mar 2, 2022, the NADAC for QUETIAPINE FUMARATE 300 MG TAB has ranged from a low of $0.1136 (Nov 20, 2024) to a high of $0.1904 (Mar 13, 2024), with a median of $0.1408 per EA.

Are there cheaper alternatives to QUETIAPINE FUMARATE 300 MG TAB?

Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, QUETIAPINE FUMARATE 300 MG TAB, is $0.1275 per EA — about 0% below QUETIAPINE FUMARATE 300 MG TAB.

Who manufactures QUETIAPINE FUMARATE 300 MG TAB?

QUETIAPINE FUMARATE 300 MG TAB (NDC 16571072101) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.